Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKWELL MEDICAL, INC.RMTI · Entity 7426 | Director | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKWELL MEDICAL, INC.
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,985 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 9,633 · Balance 23,985 F1: Restricted stock units vest on July 1, 2027, subject to the Reporting Person's continued service to the Issuer through the 2027 Annual Meeting. F2: Effective at 12:01 AM on July 1, 2026, the Issuer effected a 1-for-10 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, the shares listed under Amount of Securities Beneficially Owned Following Reported Transaction(s) reported in this Form 4 have been adjusted to reflect the 1-for-10 reverse split. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units vest on July 1, 2027, subject to the Reporting Person's continued service to the Issuer through the 2027 Annual Meeting.
F2: Effective at 12:01 AM on July 1, 2026, the Issuer effected a 1-for-10 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, the shares listed under Amount of Securities Beneficially Owned Following Reported Transaction(s) reported in this Form 4 have been adjusted to reflect the 1-for-10 reverse split.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Paratek Pharmaceuticals, Inc.
Report date September 21, 2023 · Filed September 21, 2023
Section 16 reporting ended · disclosed 2023-09-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2023-09-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-09-21 · Disposition to issuer · Disposed 53,000 · Balance 20,000 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, F2: (Continued from Footnote 1) without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC. F3: Due to administrative error, the Reporting Person's previous Form 4 filings under-reported the securities beneficially owned by the Reporting Person by 750 shares of common stock of the Issuer. This filing corrects such error and lists the correct amount of securities beneficially owned directly by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-09-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration, F5: (Continued from Footnote 4) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2031-02-18 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-21 · Disposition to issuer · Disposed 7,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2030-02-19 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-21 · Disposition to issuer · Disposed 7,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.23 · Expires 2029-02-26 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.15 · Expires 2028-02-14 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.10 · Expires 2027-02-01 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-09-21 · Disposition to issuer · Disposed 6,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.05 · Expires 2026-02-03 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-09-21 · Disposition to issuer · Disposed 12,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.07 · Expires 2029-02-26 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-09-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash,
F2: (Continued from Footnote 1) without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC.
F3: Due to administrative error, the Reporting Person's previous Form 4 filings under-reported the securities beneficially owned by the Reporting Person by 750 shares of common stock of the Issuer. This filing corrects such error and lists the correct amount of securities beneficially owned directly by the Reporting Person.
F4: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration,
F5: (Continued from Footnote 4) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger.
F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Zyla Life Sciences
Report date December 31, 2019 · Filed January 02, 2020
Section 16 reporting ended · disclosed 2020-01-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,915 |
Ending reported balance
After 2019-12-31 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-12-31 · Exercise / conversion · Acquired 66,000 · Balance 66,000 F1: Accelerated vesting of time-based restricted stock units pursuant to the reporting person's Separation and General Release Agreement. Such restricted stock units were scheduled to vest on March 26, 2020. The restricted stock units represent the right to receive an equal number of shares of Common Stock issued pursuant to the Zyla Life Sciences 2019 Stock-Based Incentive Compensation Plan. The shares are convertible into Common Stock immediately. Row 2 · 2019-12-31 · Exercise / conversion · Acquired 66,000 · Balance 132,000 F2: Accelerated vesting of performance-based restricted stock units pursuant to the reporting person's Separation and General Release Agreement. Such restricted stock units were eligible to vest on March 26, 2020. The restricted stock units represent the right to receive an equal number of shares of Common Stock issued pursuant to the Zyla Life Sciences 2019 Stock-Based Incentive Compensation Plan. The shares are convertible into Common Stock immediately. Row 3 · 2019-12-31 · Tax withholding · Disposed 55,085 · Balance 76,915 F3: Represents shares withheld to pay taxes applicable to vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-12-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-31 · Exercise / conversion · Acquired 66,000 · Balance 0 F4: Restricted Stock Units convert into Common Stock on a one-for-one basis. F5: On March 26, 2019, the reporting person was granted 66,000 restricted stock units that were scheduled to vest on March 26, 2020. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-12-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-31 · Exercise / conversion · Acquired 66,000 · Balance 0 F4: Restricted Stock Units convert into Common Stock on a one-for-one basis. F6: On March 26, 2019 the reporting person was granted 66,000 performance-based restricted stock units that were eligible to vest on March 26, 2020, subject to the Company's achievement of at least 75% of its 2019 Corporate Goals, as set by the Board in March 2019, with the exact number of performance-based RSUs vesting pro-rated based on the level of achievement between 75% and 100%. |
Filing footnotes · ownership attribution and instrument terms
F1: Accelerated vesting of time-based restricted stock units pursuant to the reporting person's Separation and General Release Agreement. Such restricted stock units were scheduled to vest on March 26, 2020. The restricted stock units represent the right to receive an equal number of shares of Common Stock issued pursuant to the Zyla Life Sciences 2019 Stock-Based Incentive Compensation Plan. The shares are convertible into Common Stock immediately.
F2: Accelerated vesting of performance-based restricted stock units pursuant to the reporting person's Separation and General Release Agreement. Such restricted stock units were eligible to vest on March 26, 2020. The restricted stock units represent the right to receive an equal number of shares of Common Stock issued pursuant to the Zyla Life Sciences 2019 Stock-Based Incentive Compensation Plan. The shares are convertible into Common Stock immediately.
F3: Represents shares withheld to pay taxes applicable to vesting of restricted stock units.
F4: Restricted Stock Units convert into Common Stock on a one-for-one basis.
F5: On March 26, 2019, the reporting person was granted 66,000 restricted stock units that were scheduled to vest on March 26, 2020.
F6: On March 26, 2019 the reporting person was granted 66,000 performance-based restricted stock units that were eligible to vest on March 26, 2020, subject to the Company's achievement of at least 75% of its 2019 Corporate Goals, as set by the Board in March 2019, with the exact number of performance-based RSUs vesting pro-rated based on the level of achievement between 75% and 100%.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 6, 2026 13:25 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 9,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-047121 · wk-form4_1783344313.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,985 F1 · kind: Restricted stock units vest on July 1, 2027, subject to the Reporting Person's continued service to the Issuer through the 2027 Annual Meeting. F2 · balance_after: Effective at 12:01 AM on July 1, 2026, the Issuer effected a 1-for-10 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, the shares listed under Amount of Securities Beneficially Owned Following Reported Transaction(s) reported in this Form 4 have been adjusted to reflect the 1-for-10 reverse split. Read SEC document |
| May 20, 2025 Filed May 21, 2025 23:05 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-051711 · tm2515860-6_4seq1.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,525 F1 · kind: Restricted stock units vest on May 20, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 21, 2024 Filed May 23, 2024 23:10 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 36,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-064816 · tm2415466-6_4seq1.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,525 F1 · kind: Restricted stock units vest on May 21, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Effective on May 13, 2022, the Issuer effected a 1-for-11 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:12 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $24.07 | Not disclosed |
DisclosureSEC source: 0000899243-23-019347 · doc4.xml · derivative · entry 9 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-02-26 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:12 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 12,000 | Not disclosed Strike: $14.05 | Not disclosed |
DisclosureSEC source: 0000899243-23-019347 · doc4.xml · derivative · entry 8 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-02-03 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:12 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 6,000 | Not disclosed Strike: $15.10 | Not disclosed |
DisclosureSEC source: 0000899243-23-019347 · doc4.xml · derivative · entry 7 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2027-02-01 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:12 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $14.15 | Not disclosed |
DisclosureSEC source: 0000899243-23-019347 · doc4.xml · derivative · entry 6 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2028-02-14 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:12 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $7.23 | Not disclosed |
DisclosureSEC source: 0000899243-23-019347 · doc4.xml · derivative · entry 5 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2029-02-26 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:12 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 7,000 | Not disclosed Strike: $3.51 | Not disclosed |
DisclosureSEC source: 0000899243-23-019347 · doc4.xml · derivative · entry 4 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2030-02-19 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:12 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerStock option (right to buy) · Derivative | 7,000 | Not disclosed Strike: $7.61 | Not disclosed |
DisclosureSEC source: 0000899243-23-019347 · doc4.xml · derivative · entry 3 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2031-02-18 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:12 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019347 · doc4.xml · nonDerivative · entry 2 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration, F5 · price: (Continued from Footnote 4) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:12 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerCommon Stock | 53,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019347 · doc4.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, F2 · price: (Continued from Footnote 1) without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC. F3 · balance_after: Due to administrative error, the Reporting Person's previous Form 4 filings under-reported the securities beneficially owned by the Reporting Person by 750 shares of common stock of the Issuer. This filing corrects such error and lists the correct amount of securities beneficially owned directly by the Reporting Person. Read SEC document |
| May 23, 2023 Filed May 25, 2023 20:19 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 24,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064639 · tm2316982-4_4seq1.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,404 F1 · kind: Restricted stock units vest on May 23, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 08, 2023 Filed Feb 9, 2023 21:46 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-23-000109 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,250 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 8, 2023, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:38 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069690 · tm2218111-5_4seq1.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,689 F1 · kind: Restricted stock units vest on June 7, 2023, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 17:31 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000171 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,250 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 16, 2022, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:25 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 72,857 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001628280-21-012670 · wf-form4_162439711921121.xml · derivative · entry 2 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,857 Underlying: Common Stock · 72,857 shares Expires 2031-06-17 F2 · derivative.exercise_date: Stock options shall vest in accordance with the following vesting schedule: (1) one-half (fifty percent) of the shares of Common Stock subject to this Option shall vest on June 17, 2023; and (2) the final one-half (remaining fifty percent) of the shares of Common Stock subject to this Option shall vest on June 17, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:25 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-012670 · wf-form4_162439711921121.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,689 F1 · kind: Restricted stock units vest on June 17, 2022, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:42 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0000904454-21-000236 · edgar.xml · derivative · entry 2 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2031-02-18 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 18, 2021, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:42 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000236 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,250 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 18, 2021, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:39 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 34,024 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001628280-20-008124 · wf-form4_159000715016150.xml · derivative · entry 2 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,024 Underlying: Common Stock · 34,024 shares Expires 2030-05-18 F3 · derivative.exercise_date: Stock options vest on May 18, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:39 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-008124 · wf-form4_159000715016150.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,689 F1 · kind: Restricted stock units vest on May 18, 2021, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 3,689 shares of common stock underlying unvested restricted stock units that vest based on the achievement of certain time-based milestones. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 20:27 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 6,148 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001628280-20-004457 · wf-form4_158577280946345.xml · derivative · entry 2 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,148 Underlying: Common Stock · 6,148 shares Expires 2030-03-31 F2 · derivative.exercise_date: Stock options vest on March 31, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 20:27 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 3,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-004457 · wf-form4_158577280946345.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,689 F1 · kind: Restricted stock units vest on March 31, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 21:36 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000904454-20-000242 · edgar.xml · derivative · entry 2 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-02-19 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 19, 2020, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 21:36 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000242 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,250 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 19, 2020, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 19:43 UTC | Zyla Life Sciences ZCOR · Entity 148990 | Exercise / conversionRestricted Stock Units · Derivative | 66,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000059 · edgar.xml · derivative · entry 5 Radie Robert S · CIK 0001591113 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Restricted Stock Units convert into Common Stock on a one-for-one basis. F6 · derivative.exercise_date: On March 26, 2019 the reporting person was granted 66,000 performance-based restricted stock units that were eligible to vest on March 26, 2020, subject to the Company's achievement of at least 75% of its 2019 Corporate Goals, as set by the Board in March 2019, with the exact number of performance-based RSUs vesting pro-rated based on the level of achievement between 75% and 100%. F6 · derivative.expiration_date: On March 26, 2019 the reporting person was granted 66,000 performance-based restricted stock units that were eligible to vest on March 26, 2020, subject to the Company's achievement of at least 75% of its 2019 Corporate Goals, as set by the Board in March 2019, with the exact number of performance-based RSUs vesting pro-rated based on the level of achievement between 75% and 100%. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 19:43 UTC | Zyla Life Sciences ZCOR · Entity 148990 | Exercise / conversionRestricted Stock Units · Derivative | 66,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000059 · edgar.xml · derivative · entry 4 Radie Robert S · CIK 0001591113 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Restricted Stock Units convert into Common Stock on a one-for-one basis. F5 · derivative.exercise_date: On March 26, 2019, the reporting person was granted 66,000 restricted stock units that were scheduled to vest on March 26, 2020. F5 · derivative.expiration_date: On March 26, 2019, the reporting person was granted 66,000 restricted stock units that were scheduled to vest on March 26, 2020. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 19:43 UTC | Zyla Life Sciences ZCOR · Entity 148990 | Tax withholdingCommon Stock | 55,085 | $2.50 | $137,712.50 |
DisclosureSEC source: 0001179110-20-000059 · edgar.xml · nonDerivative · entry 3 Radie Robert S · CIK 0001591113 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,915 F3 · shares: Represents shares withheld to pay taxes applicable to vesting of restricted stock units. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 19:43 UTC | Zyla Life Sciences ZCOR · Entity 148990 | Exercise / conversionCommon Stock | 66,000 | $2.50 | $165,000.00 |
DisclosureSEC source: 0001179110-20-000059 · edgar.xml · nonDerivative · entry 2 Radie Robert S · CIK 0001591113 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Accelerated vesting of performance-based restricted stock units pursuant to the reporting person's Separation and General Release Agreement. Such restricted stock units were eligible to vest on March 26, 2020. The restricted stock units represent the right to receive an equal number of shares of Common Stock issued pursuant to the Zyla Life Sciences 2019 Stock-Based Incentive Compensation Plan. The shares are convertible into Common Stock immediately. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 19:43 UTC | Zyla Life Sciences ZCOR · Entity 148990 | Exercise / conversionCommon Stock | 66,000 | $2.50 | $165,000.00 |
DisclosureSEC source: 0001179110-20-000059 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Accelerated vesting of time-based restricted stock units pursuant to the reporting person's Separation and General Release Agreement. Such restricted stock units were scheduled to vest on March 26, 2020. The restricted stock units represent the right to receive an equal number of shares of Common Stock issued pursuant to the Zyla Life Sciences 2019 Stock-Based Incentive Compensation Plan. The shares are convertible into Common Stock immediately. Read SEC document |
| March 26, 2019 Filed Mar 28, 2019 16:00 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantCommon Stock | 66,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004349 · edgar.xml · nonDerivative · entry 2 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,000 F2 · shares: Represents restricted stock units, which vest 100% on the first anniversary of the date of grant. Read SEC document |
| March 26, 2019 Filed Mar 28, 2019 16:00 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantCommon Stock | 172,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004349 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,000 F1 · shares: Represents restricted stock units, which vest in three equal annual installments on the first three anniversaries of the date of grant. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 19:41 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.23 | $0.00 |
DisclosureSEC source: 0000904454-19-000289 · edgar.xml · derivative · entry 2 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-02-26 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 26, 2019, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 19:41 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-19-000289 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 26, 2019, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 16:52 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 3,750 | $7.14 | $26,775.00 |
DisclosureSEC source: 0000904454-19-000258 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $7.09 to $7.20. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:31 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 150,000 | Not disclosed Strike: $2.38 | Not disclosed |
DisclosureSEC source: 0001179110-19-001246 · edgar.xml · derivative · entry 7 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2027-06-08 F2 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F2 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:31 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $8.13 | Not disclosed |
DisclosureSEC source: 0001179110-19-001246 · edgar.xml · derivative · entry 6 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-12-12 F2 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F2 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:31 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 150,000 | Not disclosed Strike: $8.11 | Not disclosed |
DisclosureSEC source: 0001179110-19-001246 · edgar.xml · derivative · entry 5 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2026-12-06 F2 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F2 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:31 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 265,000 | Not disclosed Strike: $8.59 | Not disclosed |
DisclosureSEC source: 0001179110-19-001246 · edgar.xml · derivative · entry 4 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 265,000 shares Expires 2025-11-20 F2 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F2 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:31 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $5.25 | Not disclosed |
DisclosureSEC source: 0001179110-19-001246 · edgar.xml · derivative · entry 3 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2024-12-04 F2 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F2 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:31 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-001246 · edgar.xml · nonDerivative · entry 2 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · shares: Consists of restricted stock units granted on March 6, 2018. F2 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:31 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerCommon Stock | 834,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-001246 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 500,000 shares of restricted stock granted on June 13, 2018. F2 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 17:31 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008652 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 834,900 F1 · shares: Represents restricted stock, 100% of which vests on the first anniversary of the date of grant. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 16:44 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003876 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,900 F1 · shares: Represents restricted stock units, which vest in four equal annual installments beginning on the first anniversary of the date of grant, subject to acceleration of vesting based upon the percentage achievement of 2018 corporate goals attained. If there is 75% or greater achievement of 2018 corporate goals, 100% of the RSUs will vest on the first anniversary of the grant date and if there is less than 75% achievement of 2018 corporate goals, the RSUs will remain subject to the time-based vesting schedule. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 17:24 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $14.15 | $0.00 |
DisclosureSEC source: 0000904454-18-000203 · edgar.xml · derivative · entry 2 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-02-14 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option was granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective January 1, 2018. The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 14, 2018, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 17:24 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000203 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective January 1, 2018. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 14, 2018, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 19:18 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 3,000 | $14.22 | $42,660.00 |
DisclosureSEC source: 0000904454-18-000141 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.43, inclusive. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:39 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001179110-17-008923 · edgar.xml · derivative · entry 1 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-06-08 F1 · derivative.exercise_date: 25% of the options will vest on the later of (i) the 6-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $3.33 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. 25% of the options will vest on the later of (i) the 12-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.05 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. The remaining 50% of the options will vest on the later of (i) the 24-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.76 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 19:21 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $15.10 | $0.00 |
DisclosureSEC source: 0000904454-17-000105 · edgar.xml · derivative · entry 2 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-02-01 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The shares shall vest as to 1/12 of the shares on the one-month anniversary following February 2, 2017, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service to the Company at each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.